| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 117 | 2022 | 4146 | 2.880 |
Why?
|
| Kidney Failure, Chronic | 24 | 2020 | 2426 | 1.050 |
Why?
|
| Graft Rejection | 50 | 2015 | 4228 | 0.800 |
Why?
|
| Acute Kidney Injury | 12 | 2020 | 1884 | 0.710 |
Why?
|
| Immunosuppressive Agents | 27 | 2019 | 4077 | 0.640 |
Why?
|
| Cyclosporine | 7 | 2004 | 752 | 0.610 |
Why?
|
| Organ Transplantation | 10 | 2022 | 1137 | 0.600 |
Why?
|
| Bone Marrow Transplantation | 12 | 2019 | 2661 | 0.580 |
Why?
|
| Cytomegalovirus Infections | 22 | 2001 | 829 | 0.580 |
Why?
|
| Complement C4b | 10 | 2011 | 132 | 0.530 |
Why?
|
| Renal Dialysis | 13 | 2019 | 1746 | 0.530 |
Why?
|
| Virus Diseases | 9 | 2000 | 721 | 0.520 |
Why?
|
| Hydroxyurea | 1 | 2016 | 282 | 0.490 |
Why?
|
| HLA Antigens | 14 | 2019 | 1336 | 0.480 |
Why?
|
| Polycythemia Vera | 1 | 2016 | 158 | 0.480 |
Why?
|
| Urinary Tract Infections | 18 | 1997 | 814 | 0.460 |
Why?
|
| Kidney Diseases | 18 | 2014 | 2062 | 0.430 |
Why?
|
| Nephrotic Syndrome | 2 | 2016 | 391 | 0.430 |
Why?
|
| Opportunistic Infections | 6 | 1995 | 377 | 0.380 |
Why?
|
| Immune Tolerance | 11 | 2019 | 2222 | 0.380 |
Why?
|
| Transplantation, Homologous | 34 | 2022 | 4644 | 0.380 |
Why?
|
| Mycophenolic Acid | 6 | 2004 | 336 | 0.360 |
Why?
|
| Creatinine | 11 | 2012 | 1899 | 0.350 |
Why?
|
| Tacrolimus | 7 | 2005 | 723 | 0.350 |
Why?
|
| Bacterial Infections | 8 | 1994 | 1401 | 0.350 |
Why?
|
| Tissue Donors | 13 | 2011 | 2250 | 0.350 |
Why?
|
| Transplantation Tolerance | 6 | 2015 | 568 | 0.350 |
Why?
|
| Graft Survival | 16 | 2019 | 3657 | 0.330 |
Why?
|
| Multiple Myeloma | 7 | 2019 | 5120 | 0.330 |
Why?
|
| Membranes, Artificial | 5 | 1998 | 366 | 0.310 |
Why?
|
| Isoantibodies | 7 | 2014 | 641 | 0.300 |
Why?
|
| Antibodies, Anticardiolipin | 2 | 2004 | 62 | 0.290 |
Why?
|
| Postoperative Complications | 28 | 2019 | 15579 | 0.280 |
Why?
|
| Antilymphocyte Serum | 13 | 2006 | 472 | 0.280 |
Why?
|
| Intensive Care Units | 1 | 2020 | 3710 | 0.270 |
Why?
|
| Kidney Tubular Necrosis, Acute | 5 | 2019 | 62 | 0.270 |
Why?
|
| Transplantation Chimera | 7 | 2019 | 589 | 0.270 |
Why?
|
| Glomerular Filtration Rate | 5 | 2010 | 2115 | 0.270 |
Why?
|
| Histocompatibility Testing | 9 | 2019 | 688 | 0.250 |
Why?
|
| Hepatitis C | 10 | 2011 | 1580 | 0.250 |
Why?
|
| Kidney Glomerulus | 6 | 2011 | 565 | 0.250 |
Why?
|
| Kidney | 24 | 2019 | 7009 | 0.250 |
Why?
|
| Mycoses | 5 | 2000 | 383 | 0.230 |
Why?
|
| Liver Transplantation | 11 | 2013 | 2292 | 0.220 |
Why?
|
| Biomarkers, Pharmacological | 2 | 2020 | 159 | 0.200 |
Why?
|
| Cytomegalovirus | 8 | 2001 | 756 | 0.190 |
Why?
|
| Kidney Tubules, Proximal | 3 | 2015 | 379 | 0.190 |
Why?
|
| Micropore Filters | 1 | 2020 | 22 | 0.190 |
Why?
|
| Pancreas Transplantation | 6 | 1998 | 195 | 0.180 |
Why?
|
| Biocompatible Materials | 4 | 1998 | 1686 | 0.180 |
Why?
|
| Transplantation | 3 | 1991 | 217 | 0.170 |
Why?
|
| Bence Jones Protein | 1 | 2019 | 18 | 0.170 |
Why?
|
| Hepatitis C, Chronic | 1 | 2008 | 1029 | 0.170 |
Why?
|
| Humans | 176 | 2022 | 755562 | 0.160 |
Why?
|
| Complement C4 | 6 | 2002 | 244 | 0.160 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2019 | 169 | 0.160 |
Why?
|
| Middle Aged | 74 | 2020 | 218062 | 0.160 |
Why?
|
| Immunocompromised Host | 3 | 2001 | 856 | 0.150 |
Why?
|
| Male | 87 | 2020 | 356589 | 0.150 |
Why?
|
| Lanthanum | 1 | 2017 | 30 | 0.150 |
Why?
|
| Uremia | 3 | 1990 | 200 | 0.140 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2017 | 46 | 0.140 |
Why?
|
| Hyperphosphatemia | 1 | 2017 | 39 | 0.140 |
Why?
|
| Kidney Neoplasms | 3 | 2020 | 4307 | 0.140 |
Why?
|
| Peritoneal Dialysis | 2 | 2011 | 146 | 0.140 |
Why?
|
| Adult | 81 | 2020 | 217991 | 0.140 |
Why?
|
| Peptide Fragments | 10 | 2011 | 5088 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 12 | 2006 | 9109 | 0.140 |
Why?
|
| Amoxicillin | 5 | 1984 | 178 | 0.130 |
Why?
|
| Antiviral Agents | 8 | 2008 | 3043 | 0.130 |
Why?
|
| B-Cell Activating Factor | 1 | 2015 | 116 | 0.130 |
Why?
|
| Cyclosporins | 4 | 1990 | 215 | 0.120 |
Why?
|
| Ganciclovir | 4 | 2000 | 253 | 0.120 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 1997 | 2198 | 0.120 |
Why?
|
| Antibodies | 8 | 2022 | 2415 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2020 | 965 | 0.120 |
Why?
|
| Vascular Diseases | 2 | 2022 | 1178 | 0.120 |
Why?
|
| Nephritis, Interstitial | 1 | 2015 | 155 | 0.120 |
Why?
|
| Female | 86 | 2020 | 387930 | 0.120 |
Why?
|
| Heparin | 2 | 2020 | 1652 | 0.110 |
Why?
|
| Time Factors | 26 | 2011 | 39963 | 0.110 |
Why?
|
| Antigen-Antibody Complex | 1 | 2015 | 512 | 0.110 |
Why?
|
| Ceftriaxone | 1 | 2014 | 172 | 0.110 |
Why?
|
| Hyperoxaluria, Primary | 1 | 2013 | 24 | 0.110 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2020 | 801 | 0.110 |
Why?
|
| Glomerulonephritis | 4 | 2004 | 338 | 0.110 |
Why?
|
| Interferon-alpha | 3 | 2008 | 915 | 0.110 |
Why?
|
| Complement Activation | 4 | 1999 | 444 | 0.110 |
Why?
|
| Fluconazole | 2 | 1990 | 145 | 0.100 |
Why?
|
| Ciprofloxacin | 3 | 1992 | 310 | 0.100 |
Why?
|
| Sulfamethoxazole | 2 | 1982 | 54 | 0.100 |
Why?
|
| Trimethoprim | 2 | 1982 | 85 | 0.100 |
Why?
|
| Sotos Syndrome | 1 | 2011 | 10 | 0.100 |
Why?
|
| ABO Blood-Group System | 2 | 2006 | 370 | 0.100 |
Why?
|
| Aged | 29 | 2020 | 167382 | 0.100 |
Why?
|
| Capillary Leak Syndrome | 1 | 2011 | 32 | 0.100 |
Why?
|
| Reproduction | 2 | 2006 | 644 | 0.090 |
Why?
|
| Iothalamic Acid | 1 | 2010 | 17 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2006 | 3208 | 0.090 |
Why?
|
| Transplantation Conditioning | 5 | 2019 | 1557 | 0.090 |
Why?
|
| Portal Vein | 1 | 2013 | 428 | 0.090 |
Why?
|
| Anti-Infective Agents | 2 | 2000 | 977 | 0.090 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 362 | 0.090 |
Why?
|
| Prostaglandins | 2 | 1981 | 397 | 0.090 |
Why?
|
| Epoprostenol | 2 | 1981 | 250 | 0.090 |
Why?
|
| Diabetic Nephropathies | 3 | 1995 | 979 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2009 | 3786 | 0.090 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2011 | 124 | 0.090 |
Why?
|
| Chronic Disease | 13 | 2012 | 9180 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2001 | 4423 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 694 | 0.080 |
Why?
|
| Cryptococcosis | 1 | 1990 | 103 | 0.080 |
Why?
|
| Viremia | 6 | 1998 | 704 | 0.080 |
Why?
|
| Renal Circulation | 2 | 2002 | 292 | 0.080 |
Why?
|
| Hepatitis B | 2 | 1992 | 697 | 0.080 |
Why?
|
| Immunologic Memory | 1 | 2015 | 1331 | 0.080 |
Why?
|
| Iodine Radioisotopes | 2 | 2010 | 1031 | 0.080 |
Why?
|
| Lymphocyte Depletion | 2 | 2010 | 590 | 0.080 |
Why?
|
| Treatment Outcome | 15 | 2020 | 64540 | 0.080 |
Why?
|
| Critical Care | 2 | 2019 | 2685 | 0.080 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2010 | 462 | 0.080 |
Why?
|
| Antibody Formation | 7 | 2002 | 1381 | 0.080 |
Why?
|
| Acute Disease | 12 | 2003 | 7224 | 0.080 |
Why?
|
| Ribavirin | 2 | 2008 | 395 | 0.080 |
Why?
|
| Length of Stay | 4 | 2020 | 6430 | 0.080 |
Why?
|
| Thrombosis | 2 | 1999 | 3028 | 0.080 |
Why?
|
| Biopsy, Needle | 2 | 2012 | 1632 | 0.080 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 12926 | 0.080 |
Why?
|
| Critical Illness | 1 | 2020 | 2695 | 0.070 |
Why?
|
| Carrier Proteins | 5 | 1987 | 4942 | 0.070 |
Why?
|
| Muromonab-CD3 | 3 | 1999 | 104 | 0.070 |
Why?
|
| Candidiasis | 1 | 1990 | 357 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 1864 | 0.070 |
Why?
|
| Risk Management | 1 | 2010 | 557 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2015 | 2092 | 0.070 |
Why?
|
| B-Lymphocytes | 4 | 2015 | 4706 | 0.070 |
Why?
|
| Hyponatremia | 1 | 1989 | 280 | 0.070 |
Why?
|
| Nucleoside Deaminases | 1 | 1986 | 58 | 0.070 |
Why?
|
| Podocytes | 1 | 2010 | 407 | 0.070 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 2012 | 301 | 0.070 |
Why?
|
| Patient Readmission | 2 | 2020 | 3309 | 0.070 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2006 | 363 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2012 | 10180 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2020 | 5400 | 0.070 |
Why?
|
| Antigens | 3 | 1988 | 1442 | 0.060 |
Why?
|
| Hepacivirus | 3 | 2008 | 1334 | 0.060 |
Why?
|
| Herpesviridae Infections | 3 | 1998 | 270 | 0.060 |
Why?
|
| Retrospective Studies | 15 | 2020 | 79688 | 0.060 |
Why?
|
| Biopsy | 12 | 2015 | 6760 | 0.060 |
Why?
|
| Dipeptidyl Peptidase 4 | 5 | 1987 | 90 | 0.060 |
Why?
|
| Lymphocyte Count | 1 | 2006 | 776 | 0.060 |
Why?
|
| Adenosine Deaminase | 1 | 1986 | 248 | 0.060 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 2 | 1998 | 325 | 0.060 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2014 | 1439 | 0.060 |
Why?
|
| Herpesvirus 4, Human | 5 | 1998 | 1066 | 0.060 |
Why?
|
| Reproductive Behavior | 1 | 2003 | 27 | 0.060 |
Why?
|
| Hypnosis | 1 | 1984 | 67 | 0.060 |
Why?
|
| Embolization, Therapeutic | 1 | 2013 | 1402 | 0.060 |
Why?
|
| Follow-Up Studies | 12 | 2019 | 39181 | 0.060 |
Why?
|
| Kidney Function Tests | 5 | 2004 | 681 | 0.050 |
Why?
|
| Death | 1 | 2007 | 662 | 0.050 |
Why?
|
| Radiography | 3 | 2010 | 6975 | 0.050 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2004 | 165 | 0.050 |
Why?
|
| Pyelonephritis | 3 | 1987 | 75 | 0.050 |
Why?
|
| Reoperation | 3 | 2010 | 4283 | 0.050 |
Why?
|
| Oxygen Radioisotopes | 1 | 2002 | 72 | 0.050 |
Why?
|
| Complement C3b | 2 | 1999 | 99 | 0.050 |
Why?
|
| Polyethylene Glycols | 1 | 2008 | 1180 | 0.050 |
Why?
|
| Patient Selection | 3 | 2010 | 4254 | 0.050 |
Why?
|
| Lymphopoiesis | 1 | 2002 | 132 | 0.050 |
Why?
|
| Menstruation | 1 | 2003 | 307 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 7 | 1997 | 7343 | 0.050 |
Why?
|
| Contraception Behavior | 1 | 2003 | 177 | 0.050 |
Why?
|
| Drug Therapy, Combination | 4 | 2008 | 6481 | 0.050 |
Why?
|
| Acyclovir | 2 | 2000 | 269 | 0.050 |
Why?
|
| Tumor Virus Infections | 2 | 2020 | 438 | 0.050 |
Why?
|
| Transplantation Immunology | 3 | 2015 | 507 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 2868 | 0.050 |
Why?
|
| APACHE | 2 | 1998 | 266 | 0.050 |
Why?
|
| T-Lymphocytes | 8 | 2010 | 10057 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 5566 | 0.050 |
Why?
|
| Risk Factors | 13 | 2011 | 73861 | 0.050 |
Why?
|
| Clinical Trials as Topic | 12 | 2008 | 8013 | 0.050 |
Why?
|
| Renal Artery | 3 | 1999 | 366 | 0.050 |
Why?
|
| Plasmapheresis | 1 | 2001 | 206 | 0.050 |
Why?
|
| Communicable Diseases | 1 | 1989 | 877 | 0.040 |
Why?
|
| Leukopenia | 2 | 2000 | 212 | 0.040 |
Why?
|
| Hemodynamics | 2 | 1999 | 4186 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2001 | 660 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2003 | 766 | 0.040 |
Why?
|
| Factor Xa | 1 | 2020 | 168 | 0.040 |
Why?
|
| BK Virus | 1 | 2020 | 125 | 0.040 |
Why?
|
| Immunologic Techniques | 2 | 1979 | 213 | 0.040 |
Why?
|
| Premenopause | 1 | 2003 | 1036 | 0.040 |
Why?
|
| Hospitals, General | 2 | 2001 | 767 | 0.040 |
Why?
|
| Complement Membrane Attack Complex | 1 | 1999 | 104 | 0.040 |
Why?
|
| Tomography, Emission-Computed | 1 | 2002 | 1116 | 0.040 |
Why?
|
| Virus Activation | 1 | 2001 | 319 | 0.040 |
Why?
|
| Immunization | 4 | 2001 | 1217 | 0.040 |
Why?
|
| Cystitis | 4 | 1987 | 96 | 0.040 |
Why?
|
| Resource Allocation | 2 | 2007 | 345 | 0.040 |
Why?
|
| Hepatitis, Viral, Human | 2 | 1998 | 141 | 0.040 |
Why?
|
| Community Health Nursing | 1 | 1978 | 23 | 0.040 |
Why?
|
| Technetium Tc 99m Pentetate | 2 | 1995 | 67 | 0.040 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 1998 | 112 | 0.040 |
Why?
|
| Dactinomycin | 1 | 1998 | 303 | 0.040 |
Why?
|
| Arteriosclerosis | 2 | 2001 | 1054 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2006 | 1790 | 0.040 |
Why?
|
| Polyomavirus Infections | 1 | 2020 | 196 | 0.040 |
Why?
|
| Equipment Failure Analysis | 1 | 2020 | 847 | 0.040 |
Why?
|
| Plasma Exchange | 1 | 1998 | 157 | 0.040 |
Why?
|
| Cross Infection | 2 | 1992 | 1428 | 0.040 |
Why?
|
| Blood Coagulation | 2 | 2020 | 1154 | 0.040 |
Why?
|
| Cardiolipins | 1 | 1997 | 81 | 0.040 |
Why?
|
| Prognosis | 7 | 2015 | 29424 | 0.040 |
Why?
|
| Prostaglandins E | 1 | 1977 | 168 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 11898 | 0.040 |
Why?
|
| Vasodilation | 1 | 2001 | 963 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2000 | 622 | 0.040 |
Why?
|
| Phenanthridines | 1 | 1996 | 51 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2002 | 2292 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2003 | 1473 | 0.040 |
Why?
|
| Blotting, Northern | 1 | 1998 | 1544 | 0.040 |
Why?
|
| Cysts | 1 | 2002 | 685 | 0.030 |
Why?
|
| Platelet Activating Factor | 1 | 1996 | 143 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 5784 | 0.030 |
Why?
|
| Hepatic Artery | 1 | 1997 | 231 | 0.030 |
Why?
|
| Growth Substances | 1 | 1998 | 764 | 0.030 |
Why?
|
| Antibodies, Viral | 5 | 1995 | 3120 | 0.030 |
Why?
|
| Dialysis Solutions | 1 | 1996 | 33 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 6 | 1998 | 3399 | 0.030 |
Why?
|
| Proteinuria | 3 | 2010 | 587 | 0.030 |
Why?
|
| Bone Marrow | 2 | 2019 | 2902 | 0.030 |
Why?
|
| Water | 1 | 2002 | 1399 | 0.030 |
Why?
|
| Hypertension, Renovascular | 1 | 1996 | 117 | 0.030 |
Why?
|
| Kidney Tubules | 3 | 2001 | 449 | 0.030 |
Why?
|
| Rats | 4 | 2001 | 23589 | 0.030 |
Why?
|
| Adolescent | 13 | 2012 | 87237 | 0.030 |
Why?
|
| Host-Parasite Interactions | 1 | 1997 | 297 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 1978 | 971 | 0.030 |
Why?
|
| Azathioprine | 4 | 1994 | 354 | 0.030 |
Why?
|
| Antibody-Coated Bacteria Test, Urinary | 3 | 1984 | 6 | 0.030 |
Why?
|
| Escherichia coli Infections | 2 | 1997 | 524 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2020 | 1436 | 0.030 |
Why?
|
| Triazines | 1 | 1996 | 311 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2007 | 3228 | 0.030 |
Why?
|
| Combined Modality Therapy | 3 | 2013 | 8555 | 0.030 |
Why?
|
| Leukocyte Count | 3 | 2011 | 1591 | 0.030 |
Why?
|
| Mucormycosis | 1 | 1995 | 101 | 0.030 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 1984 | 124 | 0.030 |
Why?
|
| Virulence | 1 | 1997 | 1294 | 0.030 |
Why?
|
| Interferons | 3 | 2004 | 702 | 0.030 |
Why?
|
| Diabetes Mellitus | 2 | 2002 | 5844 | 0.030 |
Why?
|
| Oxalates | 1 | 2013 | 98 | 0.030 |
Why?
|
| Prospective Studies | 10 | 2004 | 53994 | 0.030 |
Why?
|
| Soft Tissue Infections | 1 | 1995 | 165 | 0.030 |
Why?
|
| Virus Replication | 1 | 2001 | 2424 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2015 | 5846 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 1997 | 1518 | 0.030 |
Why?
|
| Parathyroid Glands | 1 | 1984 | 520 | 0.030 |
Why?
|
| Protozoan Infections | 1 | 1992 | 38 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 3 | 2009 | 2667 | 0.030 |
Why?
|
| Risk Assessment | 3 | 2015 | 23957 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 10811 | 0.030 |
Why?
|
| Recurrence | 7 | 2001 | 8441 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2002 | 2671 | 0.020 |
Why?
|
| Respiratory Tract Infections | 2 | 1998 | 997 | 0.020 |
Why?
|
| Home Care Services | 1 | 1978 | 642 | 0.020 |
Why?
|
| Adenoma | 1 | 2002 | 2144 | 0.020 |
Why?
|
| Methylprednisolone | 3 | 2001 | 385 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 3 | 1988 | 1911 | 0.020 |
Why?
|
| Antibody Specificity | 2 | 2005 | 1061 | 0.020 |
Why?
|
| Fibrinolytic Agents | 1 | 1981 | 2167 | 0.020 |
Why?
|
| Pregnancy | 5 | 2006 | 29543 | 0.020 |
Why?
|
| Interferon Type I | 3 | 1983 | 554 | 0.020 |
Why?
|
| Disease Progression | 1 | 2008 | 13429 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 1998 | 1945 | 0.020 |
Why?
|
| Young Adult | 3 | 2014 | 58027 | 0.020 |
Why?
|
| Prednisone | 4 | 1994 | 1564 | 0.020 |
Why?
|
| Cell Line | 2 | 2009 | 15646 | 0.020 |
Why?
|
| Occupational Diseases | 1 | 1978 | 1484 | 0.020 |
Why?
|
| Cadaver | 5 | 2003 | 1342 | 0.020 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2011 | 288 | 0.020 |
Why?
|
| Aging | 1 | 2008 | 8594 | 0.020 |
Why?
|
| Monitoring, Physiologic | 2 | 1995 | 1768 | 0.020 |
Why?
|
| Herpes Simplex | 3 | 1983 | 473 | 0.020 |
Why?
|
| Lung Transplantation | 1 | 1999 | 1284 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 1999 | 1280 | 0.020 |
Why?
|
| Administration, Oral | 5 | 2000 | 4017 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 1980 | 873 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2008 | 12753 | 0.020 |
Why?
|
| Immunoglobulin G | 2 | 1998 | 4523 | 0.020 |
Why?
|
| Nurses | 1 | 1978 | 2460 | 0.020 |
Why?
|
| Reperfusion Injury | 1 | 1995 | 1015 | 0.020 |
Why?
|
| Acetylglucosaminidase | 1 | 1988 | 67 | 0.020 |
Why?
|
| Survival Rate | 3 | 1998 | 12782 | 0.020 |
Why?
|
| Glycoproteins | 2 | 1987 | 2199 | 0.020 |
Why?
|
| Craniofacial Abnormalities | 1 | 2011 | 316 | 0.020 |
Why?
|
| Oliguria | 2 | 1998 | 20 | 0.020 |
Why?
|
| Nephrectomy | 2 | 2006 | 1010 | 0.020 |
Why?
|
| Ethics, Medical | 1 | 1994 | 788 | 0.020 |
Why?
|
| Retinol-Binding Proteins | 1 | 1988 | 68 | 0.020 |
Why?
|
| Animals | 8 | 2002 | 167153 | 0.020 |
Why?
|
| Liver Diseases | 1 | 1977 | 1282 | 0.020 |
Why?
|
| Cardiovascular Diseases | 2 | 2004 | 15653 | 0.020 |
Why?
|
| Prevalence | 2 | 2002 | 15590 | 0.020 |
Why?
|
| Aminopeptidases | 1 | 1988 | 95 | 0.020 |
Why?
|
| Retinol-Binding Proteins, Plasma | 1 | 1988 | 94 | 0.020 |
Why?
|
| Drug Combinations | 3 | 1984 | 2011 | 0.020 |
Why?
|
| Platelet Aggregation | 2 | 1981 | 797 | 0.020 |
Why?
|
| Prostatitis | 1 | 1988 | 102 | 0.020 |
Why?
|
| Infection Control | 1 | 1995 | 976 | 0.020 |
Why?
|
| Ischemia | 1 | 1996 | 1892 | 0.020 |
Why?
|
| beta 2-Microglobulin | 1 | 1988 | 319 | 0.020 |
Why?
|
| Postoperative Period | 2 | 2004 | 1820 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2009 | 401 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 1992 | 712 | 0.020 |
Why?
|
| Random Allocation | 5 | 1987 | 2390 | 0.020 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 1999 | 1451 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2019 | 8487 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2008 | 165 | 0.020 |
Why?
|
| Renin | 2 | 1981 | 637 | 0.020 |
Why?
|
| Capillaries | 2 | 2001 | 745 | 0.020 |
Why?
|
| Safety | 2 | 2003 | 1147 | 0.020 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2011 | 680 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 1993 | 1601 | 0.020 |
Why?
|
| Catheterization, Central Venous | 1 | 2011 | 520 | 0.020 |
Why?
|
| Dyspnea | 1 | 2014 | 1346 | 0.020 |
Why?
|
| Double-Blind Method | 5 | 2014 | 12348 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 1990 | 534 | 0.020 |
Why?
|
| Granzymes | 1 | 2008 | 274 | 0.020 |
Why?
|
| Blood Group Incompatibility | 1 | 2006 | 134 | 0.020 |
Why?
|
| Bacteriuria | 2 | 1984 | 103 | 0.020 |
Why?
|
| Cytokines | 1 | 2001 | 7263 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2007 | 452 | 0.020 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2011 | 557 | 0.020 |
Why?
|
| Amdinocillin | 1 | 1985 | 7 | 0.020 |
Why?
|
| Kidney Cortex | 2 | 2002 | 168 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2002 | 2476 | 0.020 |
Why?
|
| Nephritis, Hereditary | 1 | 2006 | 78 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2002 | 18028 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 2 | 1994 | 1635 | 0.020 |
Why?
|
| Plasmacytoma | 1 | 2006 | 171 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2011 | 2496 | 0.020 |
Why?
|
| Escherichia coli | 1 | 1997 | 4211 | 0.020 |
Why?
|
| Renal Artery Obstruction | 1 | 1976 | 224 | 0.020 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 1985 | 75 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2020 | 4862 | 0.020 |
Why?
|
| Clavulanic Acids | 1 | 1984 | 11 | 0.020 |
Why?
|
| Hepatitis C Antibodies | 1 | 2004 | 145 | 0.020 |
Why?
|
| Carrier State | 1 | 1988 | 523 | 0.010 |
Why?
|
| Immunity, Cellular | 2 | 2001 | 1543 | 0.010 |
Why?
|
| Tissue and Organ Procurement | 2 | 2007 | 924 | 0.010 |
Why?
|
| Immune System | 1 | 2009 | 795 | 0.010 |
Why?
|
| Contraceptives, Oral | 1 | 2006 | 554 | 0.010 |
Why?
|
| Risk | 5 | 1992 | 9624 | 0.010 |
Why?
|
| Fibrosis | 1 | 2010 | 2020 | 0.010 |
Why?
|
| Prednisolone | 1 | 2004 | 327 | 0.010 |
Why?
|
| Steroids | 2 | 2001 | 923 | 0.010 |
Why?
|
| Renal Plasma Flow, Effective | 1 | 2002 | 4 | 0.010 |
Why?
|
| Iodohippuric Acid | 1 | 2002 | 9 | 0.010 |
Why?
|
| Child | 8 | 2012 | 79428 | 0.010 |
Why?
|
| Siblings | 1 | 2006 | 826 | 0.010 |
Why?
|
| Adenovirus Infections, Human | 1 | 1983 | 73 | 0.010 |
Why?
|
| Probenecid | 1 | 2002 | 75 | 0.010 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 1982 | 28 | 0.010 |
Why?
|
| Enterobacteriaceae Infections | 1 | 1984 | 188 | 0.010 |
Why?
|
| Injections, Intravenous | 2 | 2000 | 1382 | 0.010 |
Why?
|
| Polyomavirus | 1 | 1983 | 235 | 0.010 |
Why?
|
| Drug Resistance | 2 | 2001 | 1611 | 0.010 |
Why?
|
| Herpesvirus 3, Human | 1 | 1983 | 158 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 41119 | 0.010 |
Why?
|
| Urologic Neoplasms | 1 | 1986 | 321 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2011 | 1416 | 0.010 |
Why?
|
| Boston | 3 | 2002 | 9254 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1981 | 404 | 0.010 |
Why?
|
| HIV Antibodies | 1 | 1988 | 1294 | 0.010 |
Why?
|
| Drug Administration Schedule | 3 | 1987 | 4887 | 0.010 |
Why?
|
| Homocysteine | 1 | 2004 | 638 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 1996 | 1128 | 0.010 |
Why?
|
| Lithium | 1 | 1984 | 595 | 0.010 |
Why?
|
| Fibrinogen | 1 | 2004 | 886 | 0.010 |
Why?
|
| Family Planning Services | 1 | 2003 | 262 | 0.010 |
Why?
|
| Physicians | 1 | 1978 | 4558 | 0.010 |
Why?
|
| Hemorrhage | 2 | 1984 | 3595 | 0.010 |
Why?
|
| Herpes Zoster | 1 | 1983 | 250 | 0.010 |
Why?
|
| Cholesterol | 2 | 2004 | 2920 | 0.010 |
Why?
|
| Hepatitis | 1 | 1981 | 231 | 0.010 |
Why?
|
| Complement C3 Convertase, Alternative Pathway | 1 | 1999 | 7 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 9372 | 0.010 |
Why?
|
| Pseudomonas Infections | 1 | 1984 | 618 | 0.010 |
Why?
|
| Registries | 1 | 2015 | 8405 | 0.010 |
Why?
|
| Kidney Concentrating Ability | 3 | 1985 | 36 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 14384 | 0.010 |
Why?
|
| Inflammation | 1 | 1999 | 10717 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2006 | 2429 | 0.010 |
Why?
|
| Prenatal Care | 1 | 2006 | 1115 | 0.010 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1978 | 114 | 0.010 |
Why?
|
| Organizational Affiliation | 1 | 1978 | 34 | 0.010 |
Why?
|
| Diabetes Complications | 2 | 2001 | 1341 | 0.010 |
Why?
|
| Incidence | 3 | 2003 | 21240 | 0.010 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1999 | 105 | 0.010 |
Why?
|
| Uric Acid | 1 | 2004 | 797 | 0.010 |
Why?
|
| Chimera | 1 | 1999 | 450 | 0.010 |
Why?
|
| Body Temperature | 1 | 1981 | 773 | 0.010 |
Why?
|
| Age Factors | 4 | 1994 | 18366 | 0.010 |
Why?
|
| Ampicillin | 1 | 1978 | 140 | 0.010 |
Why?
|
| Prostaglandins A | 1 | 1977 | 13 | 0.010 |
Why?
|
| Prostaglandins F | 1 | 1977 | 80 | 0.010 |
Why?
|
| Women | 1 | 1979 | 226 | 0.010 |
Why?
|
| Prostaglandins, Synthetic | 1 | 1977 | 24 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 12160 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 11028 | 0.010 |
Why?
|
| Natriuresis | 1 | 1977 | 105 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 1977 | 182 | 0.010 |
Why?
|
| Diuresis | 1 | 1977 | 110 | 0.010 |
Why?
|
| Polymethyl Methacrylate | 1 | 1998 | 132 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 4574 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2007 | 6521 | 0.010 |
Why?
|
| Genotype | 1 | 2011 | 12891 | 0.010 |
Why?
|
| Models, Chemical | 1 | 1999 | 615 | 0.010 |
Why?
|
| Papillomaviridae | 1 | 1983 | 1105 | 0.010 |
Why?
|
| Blood Transfusion | 2 | 1985 | 1321 | 0.010 |
Why?
|
| Central Nervous System Diseases | 1 | 1981 | 521 | 0.010 |
Why?
|
| Blood Pressure | 2 | 2004 | 8495 | 0.010 |
Why?
|
| Proportional Hazards Models | 2 | 2004 | 12500 | 0.010 |
Why?
|
| Adsorption | 1 | 1996 | 197 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 4016 | 0.010 |
Why?
|
| Sepsis | 2 | 1981 | 2592 | 0.010 |
Why?
|
| Child, Preschool | 4 | 2005 | 41893 | 0.010 |
Why?
|
| Enalapril | 1 | 1997 | 310 | 0.010 |
Why?
|
| Reperfusion | 1 | 1996 | 270 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1995 | 188 | 0.010 |
Why?
|
| Mice | 1 | 2002 | 80750 | 0.010 |
Why?
|
| Antibodies, Bacterial | 2 | 1979 | 1460 | 0.010 |
Why?
|
| Sulfones | 1 | 1998 | 448 | 0.010 |
Why?
|
| Macrophages | 1 | 1990 | 5704 | 0.010 |
Why?
|
| Living Donors | 1 | 1999 | 630 | 0.010 |
Why?
|
| Wound Healing | 1 | 1986 | 2782 | 0.010 |
Why?
|
| C-Reactive Protein | 2 | 2004 | 3812 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1998 | 979 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1998 | 2560 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1995 | 283 | 0.010 |
Why?
|
| Serum Albumin | 1 | 1998 | 677 | 0.010 |
Why?
|
| United States | 3 | 2011 | 71889 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2004 | 2412 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2007 | 5496 | 0.010 |
Why?
|
| Methods | 1 | 1984 | 1077 | 0.010 |
Why?
|
| Syndrome | 2 | 1977 | 3276 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1999 | 1831 | 0.010 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 1986 | 2104 | 0.010 |
Why?
|
| Microcirculation | 1 | 1999 | 1280 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 15746 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 19987 | 0.010 |
Why?
|
| Urography | 2 | 1983 | 314 | 0.010 |
Why?
|
| Peroxidase | 1 | 1996 | 601 | 0.010 |
Why?
|
| Phenotype | 1 | 2011 | 16478 | 0.010 |
Why?
|
| Patient Compliance | 1 | 1984 | 2684 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2006 | 5938 | 0.010 |
Why?
|
| Hypocalcemia | 1 | 1984 | 197 | 0.010 |
Why?
|
| Catheter Ablation | 1 | 2006 | 2734 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 1984 | 2606 | 0.010 |
Why?
|
| Monitoring, Immunologic | 1 | 1993 | 95 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2002 | 1868 | 0.010 |
Why?
|
| Pentamidine | 1 | 1992 | 44 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1983 | 1400 | 0.010 |
Why?
|
| Kinetics | 3 | 1985 | 6373 | 0.010 |
Why?
|
| Pneumonia | 2 | 1981 | 2126 | 0.010 |
Why?
|
| Cause of Death | 1 | 2003 | 3707 | 0.010 |
Why?
|
| Reference Values | 1 | 1999 | 4914 | 0.010 |
Why?
|
| Aldosterone | 1 | 1977 | 869 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1998 | 2846 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2001 | 2148 | 0.010 |
Why?
|
| Catheterization | 1 | 1977 | 1430 | 0.010 |
Why?
|
| Hospitalization | 1 | 2011 | 10683 | 0.010 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1992 | 246 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 1984 | 3580 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1997 | 1523 | 0.010 |
Why?
|
| Polymers | 1 | 1998 | 1613 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2002 | 2974 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1980 | 1905 | 0.010 |
Why?
|
| Contrast Media | 1 | 1983 | 5293 | 0.010 |
Why?
|
| Aerosols | 1 | 1992 | 632 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1994 | 1978 | 0.010 |
Why?
|
| Quality of Life | 1 | 1991 | 13201 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2000 | 6793 | 0.010 |
Why?
|
| RNA, Viral | 1 | 1997 | 2828 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 1995 | 2316 | 0.010 |
Why?
|
| Anxiety | 1 | 1984 | 4484 | 0.010 |
Why?
|
| Cryptococcus neoformans | 1 | 1989 | 121 | 0.010 |
Why?
|
| Candida | 1 | 1989 | 165 | 0.000 |
Why?
|
| Laparoscopy | 1 | 2001 | 2152 | 0.000 |
Why?
|
| Stress, Psychological | 1 | 1984 | 4378 | 0.000 |
Why?
|
| Cell Division | 1 | 1995 | 4447 | 0.000 |
Why?
|
| Massachusetts | 1 | 2001 | 8735 | 0.000 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 1983 | 971 | 0.000 |
Why?
|
| Leukocytes | 1 | 1995 | 2030 | 0.000 |
Why?
|
| Heart Rate | 1 | 1999 | 4104 | 0.000 |
Why?
|
| Radioisotope Renography | 1 | 1976 | 63 | 0.000 |
Why?
|
| Socioeconomic Factors | 1 | 1980 | 7782 | 0.000 |
Why?
|
| Terminal Care | 1 | 1978 | 1748 | 0.000 |
Why?
|
| Remission, Spontaneous | 1 | 1976 | 382 | 0.000 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 1985 | 200 | 0.000 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1996 | 8168 | 0.000 |
Why?
|
| Aged, 80 and over | 2 | 2005 | 58551 | 0.000 |
Why?
|
| Drug Stability | 1 | 1985 | 290 | 0.000 |
Why?
|
| Isoantigens | 1 | 1987 | 496 | 0.000 |
Why?
|
| Histocompatibility Antigens | 1 | 1985 | 452 | 0.000 |
Why?
|
| Costs and Cost Analysis | 1 | 1990 | 1674 | 0.000 |
Why?
|
| Amoxicillin-Potassium Clavulanate Combination | 1 | 1984 | 34 | 0.000 |
Why?
|
| Patient Care Team | 1 | 1995 | 2503 | 0.000 |
Why?
|
| Half-Life | 1 | 1985 | 650 | 0.000 |
Why?
|
| Binding, Competitive | 1 | 1985 | 1142 | 0.000 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1985 | 354 | 0.000 |
Why?
|
| Hepatitis B Vaccines | 1 | 1985 | 184 | 0.000 |
Why?
|
| Decision Making | 1 | 1998 | 3898 | 0.000 |
Why?
|
| Cross-Sectional Studies | 1 | 2005 | 25698 | 0.000 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1985 | 301 | 0.000 |
Why?
|
| Skin Diseases, Infectious | 1 | 1984 | 74 | 0.000 |
Why?
|
| Molecular Conformation | 1 | 1985 | 550 | 0.000 |
Why?
|
| Diabetes Insipidus | 1 | 1984 | 146 | 0.000 |
Why?
|
| Triglycerides | 1 | 1991 | 2470 | 0.000 |
Why?
|
| Autoradiography | 1 | 1984 | 737 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 2001 | 21906 | 0.000 |
Why?
|
| Logistic Models | 1 | 1998 | 13315 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1984 | 2082 | 0.000 |
Why?
|
| Immunoenzyme Techniques | 1 | 1985 | 1708 | 0.000 |
Why?
|
| Immunoassay | 1 | 1985 | 747 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 13210 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1985 | 2515 | 0.000 |
Why?
|
| Liver Function Tests | 1 | 1981 | 526 | 0.000 |
Why?
|
| Gonorrhea | 1 | 1984 | 339 | 0.000 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 1983 | 3033 | 0.000 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1983 | 1415 | 0.000 |
Why?
|
| Hypertension | 2 | 1990 | 8527 | 0.000 |
Why?
|
| Urinary Catheterization | 1 | 1979 | 202 | 0.000 |
Why?
|
| Urine | 1 | 1979 | 364 | 0.000 |
Why?
|
| Glucuronidase | 1 | 1979 | 204 | 0.000 |
Why?
|
| Urinary Bladder Diseases | 1 | 1978 | 170 | 0.000 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1983 | 1757 | 0.000 |
Why?
|
| Infant | 1 | 1978 | 35867 | 0.000 |
Why?
|
| Placebos | 1 | 1980 | 1667 | 0.000 |
Why?
|
| Simplexvirus | 1 | 1979 | 804 | 0.000 |
Why?
|
| Blood Glucose | 1 | 1988 | 6347 | 0.000 |
Why?
|
| Bacteria | 1 | 1984 | 2175 | 0.000 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1990 | 10248 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1979 | 2597 | 0.000 |
Why?
|
| Fever | 1 | 1977 | 1613 | 0.000 |
Why?
|
| Sex Factors | 1 | 1982 | 10493 | 0.000 |
Why?
|
| Pneumonia, Viral | 1 | 1977 | 3202 | 0.000 |
Why?
|